Verona Pharma

NASDAQ: VRNA · Real-Time Price · USD
105.25
-0.02 (-0.02%)
At close: Aug 15, 2025, 2:55 PM

Verona Pharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
118.53M 42.28M 6.56M 940.06K 940.06K 940.06K 458K 458K 458K 458K n/a 40M 40M 40M 40M n/a n/a
Cost of Revenue
6.26M 3.12M 1.29M 897.06K 784.26K 679.84K 816.03K 817.59K 823.65K 665.23K 319.23K 163.56K n/a n/a n/a n/a n/a
Gross Profit
112.28M 39.16M 5.28M 43K 155.79K 260.22K -358.03K -359.59K -365.65K -207.23K -319.23K 39.84M 40M 40M 40M n/a n/a
Operating Income
-137.82M -154.69M -155.61M -129.67M -71.14M -66.16M -61.15M -61.55M -72.09M -74.95M -89.17M -67.48M -75.52M -73.31M -72.89M -100.61M -82.55M
Interest Income
15.79M 15.26M 14.59M 13.23M 13.49M 12.79M 11.33M 8.72M 5.48M 2.82M 962K 187K 25K 14K 16K 25K 56K
Pretax Income
-155.57M -164.63M -154.42M -126.35M -64.1M -55.06M -50.13M -51.07M -60.26M -68.45M -81.54M -54.78M -59.13M -55.59M -49.97M -83.3M -72.06M
Net Income
-164.02M -173.48M -153.91M -125.64M -63.53M -54.49M -50.69M -51.65M -60.61M -68.7M -81.51M -54.81M -59.12M -55.57M -56.04M -86.96M -73.94M
Selling & General & Admin
198.21M 149.26M 119.07M 97.22M 60.84M 50.27M 43.7M 35.64M 28.73M 26.58M 24.01M 29.61M 32.06M 33.91M 39.84M 37.41M 32.28M
Research & Development
51.89M 44.59M 40.88M 33.29M 11.4M 17.25M 19.93M 26.81M 44.27M 49.28M 65.15M 77.88M 83.46M 79.41M 73.05M 63.2M 50.27M
Other Expenses
270.3K 270.3K 270.3K 270.3K n/a -2.31M -3.11M -5.24M -10.64M -9.63M -13.81M -16.43M -14.86M -15.63M -18.92M -14.17M -10.34M
Operating Expenses
250.1M 193.85M 159.95M 130.51M 74.18M 67.15M 62.46M 59.15M 62.35M 66.23M 75.35M 91.05M 100.66M 97.68M 93.97M 86.44M 72.21M
Interest Expense
11.78M 23.54M 13.85M 4.37M 3.36M 2.06M 1.66M 1.38M 730K 521K 376K 346K 340K 340K -1.15M -1.23M -1.32M
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a 1.13M 1.13M 1.13M 1.13M -11.51M -11.51M -11.51M -11.51M n/a n/a n/a
Cost & Expenses
256.36M 196.97M 161.23M 131.25M 74.65M 67.36M 62.81M 59.5M 62.7M 66.57M 75.35M 91.05M 100.66M 97.68M 93.97M 86.44M 72.21M
Income Tax Expense
8.45M 8.86M -510.37K -804.37K -661.55K -657.46K 467K 575K 344K 253K -25K 38K -16K -18K 6.08M 3.66M 1.88M
Shares Outstanding (Basic)
84.93M 81.54M 81.49M 81.03M 80.71M 59.12M 79.78M 79.31M 77.68M 75.53M 65.2M 60.6M 60.24M 59.9M 69.07M 58.85M 58.68M
Shares Outstanding (Diluted)
84.93M 81.54M 81.49M 81.03M 80.71M 80.27M 79.78M 79.31M 77.68M 75.53M 68.02M 60.6M 60.24M 59.9M 64.48M 58.85M 58.68M
EPS (Basic)
-2 -2.16 -2 -1.6 -0.88 -0.75 -0.65 -0.7 -0.88 -1.12 -1.36 -0.96 -1.04 -0.96 -1.04 -1.6 -1.92
EPS (Diluted)
-2 -2.16 -1.92 -1.6 -0.79 -0.69 -0.65 -0.7 -0.88 -1.04 -1.36 -0.96 -1.04 -0.96 -0.96 -1.6 -1.92
EBITDA
-176.07M -193.17M -124.96M -103.93M -59.03M -51.83M -47.84M -49.47M -53.4M -55.37M -69.94M -43.38M -48.87M -45.87M -40.44M -70.59M -61.7M
EBIT
-122.52M -139.59M -137.91M -119.32M -59.02M -51.84M -48.47M -49.69M -59.53M -67.93M -81.16M -54.43M -58.79M -55.25M -51.11M -81.26M -68.33M
Depreciation & Amortization
1.09M 1.06M 1.01M 896.3K 783K 677K 620K 622K 630K 636K 647K 652K 639K 629K 502K 548.88K 587.98K